Antibacterial R&D at a Crossroads: We've Pushed as Hard as We Can … Now We Need to Start Pulling!

John H Rex^{1

2}, Kevin Outterson^{3

4}

Affiliations

¹ F2G Limited, Eccles, Cheshire, United Kingdom.
² McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, Texas, USA.
³ Boston University School of Law, Boston, Massachusetts, USA.
⁴ CARB-X, Boston, Massachusetts, USA.

Comment

John H Rex et al. Clin Infect Dis. 2021.

. 2021 Dec 6;73(11):e4451-e4453.

doi: 10.1093/cid/ciaa852.

John H Rex^{1

2}, Kevin Outterson^{3

4}

¹ F2G Limited, Eccles, Cheshire, United Kingdom.
² McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, Texas, USA.
³ Boston University School of Law, Boston, Massachusetts, USA.
⁴ CARB-X, Boston, Massachusetts, USA.

No abstract available

Keywords: FDA; antibacterial agents; antibiotic innovation; antibiotic resistance.

Comment on

An Analysis of Antibacterial Drug Development Trends in the United States, 1980-2019.
Dheman N, Mahoney N, Cox EM, Farley JJ, Amini T, Lanthier ML. Dheman N, et al. Clin Infect Dis. 2021 Dec 6;73(11):e4444-e4450. doi: 10.1093/cid/ciaa859. Clin Infect Dis. 2021. PMID: 32584952